Kozak & Associates Inc. Reduces Stake in Johnson & Johnson (NYSE:JNJ)

Kozak & Associates Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 17.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,657 shares of the company’s stock after selling 973 shares during the quarter. Johnson & Johnson makes up approximately 0.2% of Kozak & Associates Inc.’s investment portfolio, making the stock its 27th largest position. Kozak & Associates Inc.’s holdings in Johnson & Johnson were worth $748,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. FIDELIS iM LLC grew its position in Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after buying an additional 64 shares in the last quarter. Clearview Wealth Advisors LLC grew its position in Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after buying an additional 64 shares in the last quarter. TFG Advisers LLC grew its position in Johnson & Johnson by 0.4% during the third quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock worth $2,855,000 after buying an additional 67 shares in the last quarter. My Legacy Advisors LLC grew its position in Johnson & Johnson by 3.1% during the fourth quarter. My Legacy Advisors LLC now owns 2,222 shares of the company’s stock worth $358,000 after buying an additional 67 shares in the last quarter. Finally, Kellett Wealth Advisors LLC lifted its stake in Johnson & Johnson by 3.8% during the third quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock worth $293,000 after purchasing an additional 68 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ opened at $158.17 on Friday. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The firm’s 50 day moving average is $158.71 and its 200-day moving average is $156.69. The stock has a market capitalization of $381.15 billion, a PE ratio of 11.45, a P/E/G ratio of 2.62 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same period last year, the firm earned $2.35 earnings per share. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were paid a $1.19 dividend. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Wall Street Analyst Weigh In

A number of analysts recently commented on JNJ shares. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Raymond James increased their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.